| __timestamp | Alnylam Pharmaceuticals, Inc. | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 581800000 |
| Thursday, January 1, 2015 | 276495000 | 671900000 |
| Friday, January 1, 2016 | 382392000 | 876700000 |
| Sunday, January 1, 2017 | 390635000 | 857900000 |
| Monday, January 1, 2018 | 505420000 | 822200000 |
| Tuesday, January 1, 2019 | 655114000 | 778200000 |
| Wednesday, January 1, 2020 | 654819000 | 512600000 |
| Friday, January 1, 2021 | 792156000 | 681000000 |
| Saturday, January 1, 2022 | 883015000 | 662200000 |
| Sunday, January 1, 2023 | 1004415000 | 910700000 |
| Monday, January 1, 2024 | 1126232000 |
Unleashing the power of data
In the competitive landscape of pharmaceuticals, innovation is key. Alnylam Pharmaceuticals, Inc. and Viatris Inc. have been at the forefront of this race, each with distinct strategies. Over the past decade, Alnylam has consistently increased its research and development (R&D) spending, culminating in a 428% rise from 2014 to 2023. This aggressive investment underscores their commitment to pioneering RNA interference therapeutics. In contrast, Viatris Inc., formed in 2020, has maintained a steady R&D expenditure, reflecting its focus on leveraging existing products and markets. By 2023, Alnylam's R&D expenses surpassed Viatris by approximately 10%, highlighting their divergent paths. This comparison not only showcases the dynamic nature of pharmaceutical innovation but also emphasizes the strategic choices companies make to stay ahead. As the industry evolves, these spending patterns will likely shape the future of healthcare breakthroughs.
R&D Spending Showdown: Sanofi vs Viatris Inc.
Research and Development: Comparing Key Metrics for Gilead Sciences, Inc. and Alnylam Pharmaceuticals, Inc.
GSK plc vs Alnylam Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc. vs Madrigal Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Grifols, S.A.
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Galapagos NV
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs MiMedx Group, Inc.
Viatris Inc. or Ascendis Pharma A/S: Who Invests More in Innovation?
Research and Development Investment: Viatris Inc. vs Axsome Therapeutics, Inc.
Research and Development Investment: Viatris Inc. vs CymaBay Therapeutics, Inc.